v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development $ 27,265 $ 25,969
In-process research and development 150,000 0
General and administrative 10,646 9,661
Total operating expenses 187,911 35,630
Loss from operations (187,911) (35,630)
Other income (expense)    
Interest income 4,449 4,740
Other income (expense), net 22 (76)
Total other income (expense), net 4,471 4,664
Net loss $ (183,440) $ (30,966)
Net loss per share, basic $ (0.60) $ (0.11)
Net loss per share, diluted $ (0.60) $ (0.11)
Weighted-average shares of common stock used in computing net loss per share, basic 304,317,460 283,260,289
Weighted-average shares of common stock used in computing net loss per share, diluted 304,317,460 283,260,289
Other comprehensive income (loss):    
Unrealized (loss) gain on marketable securities, net $ (1,327) $ 223
Comprehensive loss $ (184,767) $ (30,743)